Welcome to our dedicated page for Champions Oncolo news (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncolo stock.
Champions Oncology, Inc. reports developments as a translational oncology research organization serving biopharma drug discovery and development. The company’s updates center on preclinical and clinical research services, patient-derived xenograft (PDX) and primary hematological malignancy models, proprietary in vivo and ex vivo platforms, bioanalytical capabilities, and data services that connect tumor models with molecular and clinical datasets.
Recurring news themes include quarterly operating results, study service revenue, bookings and backlog conversion, data platform investment, research presentations at oncology meetings, and governance changes. Company research updates describe model-based studies of therapeutic response, resistance, biomarkers, and tumor biology across oncology development programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Champions Oncology (NASDAQ:CSBR) has launched Corellia AI, a wholly-owned subsidiary aimed at advancing therapeutic discovery through AI-driven technology. The new entity will utilize Champions' PDX Molecular Atlas and living bank of PDX models as key tools in its platform.
Corellia AI focuses on developing first-in-class Antibody Drug Conjugates (ADCs) targeting patients with unmet needs, leveraging deep data for innovative therapeutic programs. Under the leadership of Ronnie Morris and Michael Ritchie, the initiative aims to rapidly advance these programs into clinical trials. This strategic move is seen as a natural progression in Champions’ efforts to innovate drug discovery, potentially enhancing growth in the biotech sector.
Champions Oncology (CSBR) announced a $5 million stock repurchase program authorized by its Board of Directors, valid through April 30, 2024. The company aims to utilize this program as a strategic move to enhance long-term shareholder value amidst a favorable macroeconomic environment. CEO Ronnie Morris and CFO David Miller expressed confidence in the company's prospects, emphasizing that the current market valuation does not reflect its potential. The repurchase will occur through open market transactions, with flexibility in timing and amount based on market conditions. The program can be modified or terminated at the Board's discretion.
Champions Oncology (Nasdaq: CSBR) reported its Q3 fiscal 2023 financial results, revealing a quarterly revenue of $12.8 million, a decrease of 3.2% from the previous year. The adjusted EBITDA loss was $1.6 million, primarily due to increased R&D spending. The company experienced increased operating costs, totaling $15.2 million, a 23.2% rise year-over-year. Challenges were attributed to a macroeconomic environment leading to client cancellations impacting revenue streams. Despite these setbacks, Champions' long-term strategy remains intact, with expectations for improved results in fiscal 2024.
Champions Oncology, Inc. (CSBR) will report its third-quarter financial results for the period ending January 31, 2023, on March 15, 2023, after market close. Additionally, the company will host a conference call at 4:30 P.M. EDT to discuss these results. Interested parties can participate by calling 888-506-0062 (Domestic) or 973-528-0011 (International). A replay of the call will be accessible shortly after the event. Champions Oncology specializes in AI-driven drug discovery and provides innovative therapeutic and research solutions to biopharma clients.
Champions Oncology (NASDAQ:CSBR) reported record second-quarter fiscal 2023 revenue of $14.3 million, reflecting a 21% year-over-year increase. However, the company faced a slowdown in bookings growth attributed to the challenging global economic environment, leading to increased cancellations. Adjusted EBITDA for the quarter was $686,000, a slight decrease from $743,000 the previous year. Full-year growth targets have been revised to 10%-15% due to these factors. Despite challenges, Champions maintains a strong cash position of $10.8 million and no debt.